School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
Infection Biology Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
mBio. 2019 Oct 29;10(5):e01755-19. doi: 10.1128/mBio.01755-19.
Sporadic literature reports describe isolates of pathogenic bacteria that harbor an antibiotic resistance determinant but remain susceptible to the corresponding antibiotic as a consequence of a genetic defect. Such strains represent a source from which antibiotic resistance may reemerge to cause treatment failure in patients. Here, we report a systematic investigation into the prevalence and nature of this phenomenon, which we term ilencing of ntibiotic esistance by utation (SARM). Instances of SARM were detected among 1,470 isolates through side-by-side comparison of antibiotic resistance genotype (as determined by whole-genome sequencing) versus phenotype (as assessed through susceptibility testing). Of the isolates analyzed, 152 (10.3%) harbored a silenced resistance gene, including 46 (3.1%) that exhibited SARM to currently deployed antistaphylococcal drugs. SARM resulted from diverse mutational events but most commonly through frameshift mutation of resistance determinants as a result of point deletion in poly(A) tracts. The majority (∼90%) of SARM strains reverted to antibiotic resistance at frequencies of ≥10; thus, while appearing antibiotic sensitive in the clinical microbiology laboratory, most isolates exhibiting SARM will revert to antibiotic resistance at frequencies achievable in patients. In view of its prevalence in a major pathogen, SARM represents a significant potential threat to the therapeutic efficacy of antibiotics. Antibiotic resistance hinders the treatment of bacterial infection. To guide effective therapy, clinical microbiology laboratories routinely perform susceptibility testing to determine the antibiotic sensitivity of an infecting pathogen. This approach relies on the assumption that it can reliably distinguish bacteria capable of expressing antibiotic resistance in patients, an idea challenged by the present study. We report that the important human pathogen frequently carries antibiotic resistance genes that have become inactivated ("silenced") by mutation, leading strains to appear antibiotic sensitive. However, resistance can rapidly reemerge in most such cases, at frequencies readily achievable in infected patients. Silent antibiotic resistance is therefore prevalent, transient, and evades routine detection, rendering it a significant potential threat to antibacterial chemotherapy.
零星的文献报道描述了携带抗生素耐药决定因子但由于遗传缺陷而对相应抗生素仍保持敏感的致病菌分离株。这些菌株可能成为抗生素耐药性重新出现的来源,导致患者治疗失败。在这里,我们报告了一项系统性调查,研究了这种现象的普遍性和本质,我们将其称为突变导致抗生素耐药性沉默(SARM)。通过对全基因组测序确定的抗生素耐药基因型(简称基因型)与药敏试验评估的表型(简称表型)进行并排比较,在 1470 株分离株中检测到 SARM 现象。在分析的分离株中,有 152 株(10.3%)携带沉默的耐药基因,其中 46 株(3.1%)对目前使用的抗葡萄球菌药物表现出 SARM。SARM 是由多种突变事件引起的,但最常见的是由于多聚(A)片段的点缺失导致耐药决定因素发生移码突变。大多数(约 90%)SARM 菌株的抗生素耐药性恢复频率≥10;因此,虽然在临床微生物学实验室中表现出对抗生素敏感,但大多数表现出 SARM 的分离株在患者中可达到的频率会恢复对抗生素的耐药性。鉴于其在主要病原体中的普遍性,SARM 代表了抗生素治疗效果的重大潜在威胁。抗生素耐药性阻碍了细菌感染的治疗。为了指导有效的治疗,临床微生物学实验室通常进行药敏试验,以确定感染病原体的抗生素敏感性。这种方法依赖于这样一种假设,即它可以可靠地区分能够在患者中表达抗生素耐药性的细菌,而本研究对这一观点提出了挑战。我们报告称,重要的人类病原体 经常携带抗生素耐药基因,这些基因因突变而失活(“沉默”),导致菌株表现出对抗生素敏感。然而,在大多数情况下,这种耐药性可以迅速重新出现,其频率在感染患者中很容易达到。因此,沉默的抗生素耐药性普遍存在、短暂且逃避常规检测,这对抗菌化疗构成了重大潜在威胁。